H2SITE Strengthens Its Leadership With a New Control Room, Developed in Collaboration With Siemens, to Remotely Monitor Membrane Reactor and Separator Technologies for Hydrogen Production Across Europe
27.10.2025 13:01:00 EET | Business Wire | Press release
H2SITE, the deep-tech start-up revolutionizing high-purity hydrogen production through cutting-edge palladium membrane technology, is scaling up its industrial presence with projects deployed across several European countries. To ensure performance and continuous optimization of its membrane reactors and separators, H2SITE has launched a control and data collection room built in collaboration with Siemens, based on the beta version of Siemens WinCC Unified Collaboration and Datahub software.
The control room is already integrated and will be further developed across various ongoing and future projects, covering a wide range of market segments that reflect the versatility of H2SITE’s membrane-based technology. In the field of ammonia (NH₃) cracking, projects such as EIC, APOLO, and KATA are integrating this tool to monitor hydrogen production efficiency and system reliability in real time. Within the Waste-to-Hydrogen (WtH₂) segment, the HYIELD project is applying the control room to optimize process parameters and ensure stable operation during the conversion of waste streams into clean hydrogen.
In Hydrogen Recovery applications, including AREARA, HERMES, and CleanToPureH₂ ,the platform enables continuous performance supervision, predictive maintenance, and detailed data analysis, ensuring the highest recovery rates and operational safety standards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027251795/en/
WinCC Unified System
The control room is based on the beta version of Siemens WinCC Unified Collaboration and Datahub software.
WinCC Unified is a flexible and scalable platform that unifies visualization, control, and data management within TIA Portal. Based on web standards, it provides secure access from any browser and device, ensuring data transparency, IT/OT integration, and a high level of cybersecurity. Its power and data management capabilities enable implementations ranging from simple HMIs to complete SCADA solutions, whether hyper-distributed or centralized, with maximum availability and performance.
This pioneering solution enables remote, global, real-time support and monitoring of all installed reactors through secure VPN based on SINEMA Remote Connect, even when they are integrated into complex or isolated networks. From this platform, H2SITE teams can easily visualize key indicators such as operating hours, operational KPIs, hydrogen production, energy consumption, ammonia usage, as well as live charts on temperature, pressure, and hydrogen purity. Optimizing operational efficiency and system availability
Data visualization supports agile decision-making, grounded in precise, real-time information. In addition, the control room is designed to enhance process analysis, data capture and storage, and operational optimization through intelligent dashboards.
“The implementation of this control platform is being deployed across all systems currently under commissioning or design at H2SITE. This development allows us to deliver robust, scalable, and connected solutions to our clients,” said José Medrano, Technical Director at H2SITE.
About H2SITE
H2SITE develops and commercializes reactors and membrane separation technologies for the production and recovery of high-purity hydrogen from a variety of feedstocks (ammonia, methanol, liquid organic hydrogen carriers, and gas mixtures). The company has established itself as a unique industrial player in Europe, with the capacity to design, manufacture, and deploy solutions locally to accelerate the energy transition. https://h2site.eu/
About Siemens
Siemens is a global technology company headquartered in Germany, operating in more than 190 countries. A leader in automation, digitalization, and electrification, Siemens drives innovation and efficiency across industries, infrastructure, and healthcare. Within the group, Siemens Digital Industries (DI) leads in industrial automation and digital transformation, combining hardware, software, and cloud solutions through its Xcelerator platform to help industries build a smarter, more connected, and sustainable future. www.siemens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251027251795/en/
Contacts
For more information:
Jose A. Medrano: +34 630116649; E-mail:jose.medrano@h2site.com
Raúl Ramos - Movil: +34 91 514 8221; E-mail: raul.ramos@siemens.com
Miguel Ángel Gavira - Movil: +34 91 514 8221; E-mail:
miguel.gavira_duran@siemens.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom